Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13557898 | 0.84 | PARP1 (0.42) | KDM4EACHEKMT2APARP1 | |
| SCHEMBL6124233 | 0.79 | TNKS2 (0.49) | CYP19A1SMN1; SMN2NPBWR1KDM4EMAPT | |
| SCHEMBL8247179 | 0.72 | PNMT (0.57) | HTR1ATDP2SMN1; SMN2DRD1PTPRC | |
| SCHEMBL5277109 | 0.71 | CA12 (0.53) | CYP19A1SMN1; SMN2NPBWR1MAPTCRHBP | |
| Ammonia Solution, Strong SCHEMBL7244192 | 0.70 | CA12 (0.51) | CYP19A1SMN1; SMN2NPBWR1MAPTCRHBP | |
| SCHEMBL6124153 | 0.70 | TSHR (0.53) | TDP2MAPTACHEPARP1 | |
| SCHEMBL11035541 | 0.67 | TDP2 (0.45) | HTR1ATDP2MAPTPTPRCS100A4 | |
| SCHEMBL10854713 | 0.67 | TDP2 (0.45) | HTR1ATDP2MAPTPTPRCS100A4 | |
| SCHEMBL28734719 | 0.67 | PNMT (0.48) | HTR1ATDP2SMN1; SMN2DRD1PNMT | |
| SCHEMBL29507848 | 0.67 | PNMT (0.48) | HTR1ATDP2SMN1; SMN2DRD1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133136-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133136-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8298512-B2 | Methods of determining β-III tubulin expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-8298512-B2 | Methods of determining β-III tubulin expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-8178545-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-18 | — | — | US | disclosed |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-18 | — | — | US | disclosed |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-06-14 | — | — | US | disclosed |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | HTR1A 4521/4885CYP19A1 2931/4885TDP2 898/4885 |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | TUBB3, TUBB1, TUBB | HTR1A 4457/4885CYP19A1 4089/4885TDP2 1061/4885 |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | HTR1A 4521/4885CYP19A1 2931/4885TDP2 898/4885 |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | TP53, MAP2, MAP1LC3B | HTR1A 4521/4885CYP19A1 2931/4885TDP2 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.